Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.

BACKGROUND Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose epoprostenol (EPO) was evaluated in the present study. METHODS AND RESULTS Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6+/-43.4 ng . kg(-1) . min(-1)). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99.6+/-43.4 to 82.8+/-31.3 ng . kg(-1) . min(-1), p<0.05). There was a significant decrease from the baseline value for systolic pulmonary artery pressure (80.1+/-19.3 to 66.8+/-16.5 mmHg, p<0.05). These effects were maintained for 1 year without progression of PAH in 6 patients whose condition had been stabilized at baseline. CONCLUSIONS The additional use of bosentan for IPAH patients whose condition has been stabilized by high-dose EPO is safe and effective.

[1]  M. Hori,et al.  Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[2]  K. Aonuma,et al.  Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[3]  R. Barst,et al.  Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil , 2006, European Respiratory Journal.

[4]  G. Criner,et al.  Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. , 2006, Chest.

[5]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[6]  W. Seeger,et al.  Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[7]  D. Bonderman,et al.  Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia , 2006, European journal of clinical investigation.

[8]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[9]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[10]  M. Matsuzaki,et al.  Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[11]  A. Anzueto,et al.  Efficacy of Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) in Patients Previously Naïve to COPD Maintenance Therapy , 2004 .

[12]  A. Frost,et al.  Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. , 2004, Chest.

[13]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[14]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[15]  D. Ivy,et al.  Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. , 2004, The American journal of cardiology.

[16]  M. Hoeper,et al.  Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.

[17]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[18]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[19]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[20]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[21]  G. Simonneau,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆ , 2002 .

[22]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[23]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[24]  B. Brundage,et al.  Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.

[25]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[26]  R. Barst,et al.  FOR THE PRIMARY PULM HYPERTENSION STUDY GROUP. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 1996 .

[27]  S. Rich.  Primary pulmonary hypertension , 1988 .

[28]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.